Domača stranATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Prejšnji trg. dan.
0,22 $
Letni razpon
0,11 $ - 0,89 $
Povprečni obseg
27,54 tis.
Razm. P/E
-
Dividendna donosnost
-
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (CAD) | dec. 2023info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 4,60 mio. | −1,42 % |
Čisti dohodek | −4,21 mio. | 2,39 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,08 | 0,50 % |
EBITDA | — | — |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (CAD) | dec. 2023info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 24,91 mio. | −41,20 % |
Skupna sredstva | 56,36 mio. | −23,56 % |
Skupne obveznosti | 30,42 mio. | −0,13 % |
Celoten lastniški kapital | 25,94 mio. | — |
Shares outstanding | 52,67 mio. | — |
Razmerje P/B | 0,44 | — |
Donosnost sredstev | −19,71 % | — |
Donosnost kapitala | −41,30 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (CAD) | dec. 2023info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −4,21 mio. | 2,39 % |
Denar iz dejavnosti | −3,84 mio. | −6,66 % |
Denar iz naložb | 11,04 mio. | 1.975,38 % |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | 7,20 mio. | 334,09 % |
Prost denarni tok | −2,47 mio. | −2.419,13 % |
Vizitka
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Datum ustanovitve
2009
Spletno mesto
Zaposleni
11
